Intratumoral Cancer Treatment Market 2034: EMA, PDMA, FDA Approvals, Medication, NICE Approvals, Clinical Trials, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight

Intratumoral Cancer Therapies Companies are Amgen, Daiichi Sankyo, AiViva BioPharma, Lytix Biopharma, Regeneron Pharmaceuticals, Checkmate Pharmaceuticals, OncoSec Medical Incorporated, Merck, Istari Oncology, Replimune, Philogen, Sirnaomics, Exicure, Intensity Therapeutics, NanOlogy, Nanobiotix, Immunovative Therapies, DNAtrix, Idera Pharmaceuticals, Lokon Pharma, Treovir, Immunicum, and others
(Albany, USA) DelveInsight's "Intratumoral Cancer Therapies Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Intratumoral Cancer Therapies, historical and forecasted epidemiology as well as the Intratumoral Cancer Therapies market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Intratumoral Cancer Therapies market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Intratumoral Cancer Therapies market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Intratumoral Cancer treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Intratumoral Cancer Therapies market.

To Know in detail about the Intratumoral Cancer Therapies market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Intratumoral Cancer Therapies Market Forecast [https://www.delveinsight.com/sample-request/intratumoral-cancer-therapies-market-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some of the key facts of the Intratumoral Cancer Therapies Market Report:

* The Intratumoral Cancer Therapies market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
* In January 2025, Intensity Therapeutics, Inc. (Nasdaq: INTS), a late-stage clinical biotechnology company dedicated to discovering and developing proprietary immune-based intratumoral cancer therapies, has provided a business update showcasing significant progress with its lead drug candidate, INT230-6.
* In January 2025, Lokon Pharma AB reported that the U.S. FDA granted Fast Track designation for the company's product candidate LOAd703 in the treatment of pancreatic cancer.
* In March 2024, ImmVira announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to its oncolytic virus product MVR-T3011 IT (intratumoral injection) for treating recurrent or metastatic head and neck squamous cell cancer that has progressed after platinum-based chemotherapy and at least one prior line of anti-PD1/PDL1 therapy.
* Several intratumoral therapy strategies, such as immune-enhancing cytokines, TLR and STING agonists, T-cell checkpoint inhibitors, suppressive cytokine inhibitors or traps, oncolytic viruses (OVs), and plasmid DNA, are currently undergoing clinical development for melanoma patients.
* At present, IMLYGIC is the only intratumoral therapy approved by the US FDA for melanoma treatment, capturing over 90% of the total market for intratumoral therapies.
* Among the emerging therapies, OncoSec Medical's TAVO (tavokinogene telseplasmid), a plasmid-based interleukin-12, is anticipated to generate the highest revenue.
* The United States holds around 80% of the market share for Intratumoral Cancer Therapies.
* A person's chance of surviving five years after being diagnosed with cutaneous melanoma improves with earlier diagnosis. Skin melanoma is diagnosed in 81.6% of cases at the local stage, 9% at the regional stage, and 4% at the distant stage when the cancer has spread. Skin-related localised melanoma had a 5-year relative survival rate of 99.5%
* During the prediction period (2021-2022), the United States reported 98,046 instances of melanoma; this number is expected to rise to 2032. In 2021, there were 31,636 cases of melanoma and 91,650 cases of non-melanoma skin cancer (NMSC) in Germany
* Nonmelanoma skin cancer (NMSC), one of the nine primary indications for intratumoral treatments, represented the majority of cases in the 7MM. In 2021, there were 793,007 NMSC instances in the 7MM as a whole
* Key Intratumoral Cancer Therapies Companies: Amgen, Daiichi Sankyo, AiViva BioPharma, Lytix Biopharma, Regeneron Pharmaceuticals, Checkmate Pharmaceuticals, OncoSec Medical Incorporated, Merck, Istari Oncology, Replimune, Philogen, Sirnaomics, Exicure, Intensity Therapeutics, NanOlogy, Nanobiotix, Immunovative Therapies, DNAtrix, Idera Pharmaceuticals, Lokon Pharma, Treovir, Immunicum, and others
* Key Intratumoral Cancer Therapies Therapies: IMLYGIC (talimogene laherparepvec), DELYTACT (G47), AIV001, LTX-315, Vidutolimod + nivolumab, Vidutolimod (CMP-001), Tavo (tavokinogene telseplasmid), CAVATAK (V937; CVA21), PVSRIPO (PVS-RIPO), RP1 (vusolimogene oderparepvec), Daromun (Nidlegy), Cotsiranib (STP705), Cavrotolimod (AST-008), INT230-6 (Cisplatin/vinblastine), NanoPac (LSAM paclitaxel), Hensify (NBTXR3/ PEP503), AlloStim, Tasadenoturev (DNX-2401), Tilsotolimod (IMO-2125), Delolimogene mupadenorepvec (LOAd703), G207, Intuvax (Ilixadencel), and others
* The Intratumoral Cancer Therapies market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Intratumoral Cancer Therapies pipeline products will significantly revolutionize the Intratumoral Cancer Therapies market dynamics.

Intratumoral Cancer Therapies Overview

Intratumoral cancer therapies represent a novel and promising approach in oncology, focusing on the direct injection of therapeutic agents into the tumor microenvironment. Unlike systemic therapies that circulate throughout the body, intratumoral cancer therapies aim to maximize local tumor control while minimizing systemic toxicity. This targeted method enhances the concentration of the drug within the tumor, improving efficacy and reducing side effects.

Intratumoral cancer therapies include a range of modalities such as oncolytic viruses, immunotherapies, cytokines, gene therapies, and small molecule drugs. These therapies are designed to stimulate a localized immune response that can also generate systemic anti-tumor immunity, potentially leading to tumor regression at distant sites - a phenomenon known as the abscopal effect.

Intratumoral cancer therapies are gaining traction in clinical trials for various cancers, including melanoma, head and neck cancers, and triple-negative breast cancer. Their ability to modulate the tumor microenvironment and enhance immune cell infiltration makes them a key player in combination strategies with checkpoint inhibitors and other immuno-oncology treatments.

Despite their potential, intratumoral cancer therapies face challenges such as optimal delivery methods, tumor accessibility, and standardization of treatment protocols. Ongoing research and technological advancements are expected to overcome these hurdles and drive future growth in this field.

Get a Free sample for the Intratumoral Cancer Therapies Market Report - https://www.delveinsight.com/report-store/intratumoral-cancer-therapies-market-insight [https://www.delveinsight.com/report-store/intratumoral-cancer-therapies-market-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Intratumoral Cancer Therapies Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Intratumoral Cancer Therapies Epidemiology Segmentation:

The Intratumoral Cancer Therapies market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

* Total Prevalence of Intratumoral Cancer Therapies
* Prevalent Cases of Intratumoral Cancer Therapies by severity
* Gender-specific Prevalence of Intratumoral Cancer Therapies
* Diagnosed Cases of Episodic and Chronic Intratumoral Cancer Therapies

Download the report to understand which factors are driving Intratumoral Cancer Therapies epidemiology trends @ Intratumoral Cancer Therapies Epidemiology Forecast [https://www.delveinsight.com/sample-request/intratumoral-cancer-therapies-market-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Intratumoral Cancer Therapies Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Intratumoral Cancer Therapies market or expected to get launched during the study period. The analysis covers Intratumoral Cancer Therapies market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Intratumoral Cancer Therapies Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Intratumoral Cancer Therapies Therapies and Key Companies

* IMLYGIC (talimogene laherparepvec): Amgen
* DELYTACT (G47): Daiichi Sankyo
* AIV001: AiViva BioPharma
* LTX-315: Lytix Biopharma
* Vidutolimod + nivolumab: Regeneron Pharmaceuticals
* Vidutolimod (CMP-001): Checkmate Pharmaceuticals
* Tavo (tavokinogene telseplasmid): OncoSec Medical Incorporated
* CAVATAK (V937; CVA21): Merck
* PVSRIPO (PVS-RIPO): Istari Oncology
* RP1 (vusolimogene oderparepvec): Replimune/ Regeneron
* Daromun (Nidlegy): Philogen
* Cotsiranib (STP705): Sirnaomics
* Cavrotolimod (AST-008): Exicure
* INT230-6 (Cisplatin/vinblastine): Intensity Therapeutics
* NanoPac (LSAM paclitaxel): NanOlogy
* Hensify (NBTXR3/ PEP503): Nanobiotix
* AlloStim: Immunovative Therapies
* Tasadenoturev (DNX-2401): DNAtrix
* Tilsotolimod (IMO-2125): Idera Pharmaceuticals
* Delolimogene mupadenorepvec (LOAd703): Lokon Pharma
* G207: Treovir
* Intuvax (Ilixadencel): Immunicum

Discover more about therapies set to grab major Intratumoral Cancer Therapies market share @ Intratumoral Cancer Treatment Market [https://www.delveinsight.com/sample-request/intratumoral-cancer-therapies-market-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Scope of the Intratumoral Cancer Therapies Market Report

* Study Period: 2020-2034
* Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
* Key Intratumoral Cancer Therapies Companies: Amgen, Daiichi Sankyo, AiViva BioPharma, Lytix Biopharma, Regeneron Pharmaceuticals, Checkmate Pharmaceuticals, OncoSec Medical Incorporated, Merck, Istari Oncology, Replimune, Philogen, Sirnaomics, Exicure, Intensity Therapeutics, NanOlogy, Nanobiotix, Immunovative Therapies, DNAtrix, Idera Pharmaceuticals, Lokon Pharma, Treovir, Immunicum, and others
* Key Intratumoral Cancer Therapies Therapies: IMLYGIC (talimogene laherparepvec), DELYTACT (G47), AIV001, LTX-315, Vidutolimod + nivolumab, Vidutolimod (CMP-001), Tavo (tavokinogene telseplasmid), CAVATAK (V937; CVA21), PVSRIPO (PVS-RIPO), RP1 (vusolimogene oderparepvec), Daromun (Nidlegy), Cotsiranib (STP705), Cavrotolimod (AST-008), INT230-6 (Cisplatin/vinblastine), NanoPac (LSAM paclitaxel), Hensify (NBTXR3/ PEP503), AlloStim, Tasadenoturev (DNX-2401), Tilsotolimod (IMO-2125), Delolimogene mupadenorepvec (LOAd703), G207, Intuvax (Ilixadencel), and others
* Intratumoral Cancer Therapies Therapeutic Assessment: Intratumoral Cancer Therapies current marketed and Intratumoral Cancer Therapies emerging therapies
* Intratumoral Cancer Therapies Market Dynamics: Intratumoral Cancer Therapies market drivers and Intratumoral Cancer Therapies market barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Intratumoral Cancer Therapies Unmet Needs, KOL's views, Analyst's views, Intratumoral Cancer Therapies Market Access and Reimbursement

To know more about Intratumoral Cancer Therapies companies working in the treatment market, visit @ Intratumoral Cancer Therapies Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/intratumoral-cancer-therapies-market-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Table of Contents

1. Intratumoral Cancer Therapies Market Report Introduction

2. Executive Summary for Intratumoral Cancer Therapies

3. SWOT analysis of Intratumoral Cancer Therapies

4. Intratumoral Cancer Therapies Patient Share (%) Overview at a Glance

5. Intratumoral Cancer Therapies Market Overview at a Glance

6. Intratumoral Cancer Therapies Disease Background and Overview

7. Intratumoral Cancer Therapies Epidemiology and Patient Population

8. Country-Specific Patient Population of Intratumoral Cancer Therapies

9. Intratumoral Cancer Therapies Current Treatment and Medical Practices

10. Intratumoral Cancer Therapies Unmet Needs

11. Intratumoral Cancer Therapies Emerging Therapies

12. Intratumoral Cancer Therapies Market Outlook

13. Country-Wise Intratumoral Cancer Therapies Market Analysis (2020-2034)

14. Intratumoral Cancer Therapies Market Access and Reimbursement of Therapies

15. Intratumoral Cancer Therapies Market Drivers

16. Intratumoral Cancer Therapies Market Barriers

17. Intratumoral Cancer Therapies Appendix

18. Intratumoral Cancer Therapies Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=intratumoral-cancer-treatment-market-2034-ema-pdma-fda-approvals-medication-nice-approvals-clinical-trials-revenue-statistics-therapies-prevalence-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.